CINVANTI
Total Payments
$1.4M
Transactions
2,238
Doctors
1,159
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $889.20 | 13 | 11 |
| 2023 | $12,466 | 79 | 73 |
| 2022 | $12,142 | 416 | 302 |
| 2021 | $155,092 | 14 | 2 |
| 2020 | $366,667 | 236 | 159 |
| 2019 | $391,094 | 688 | 413 |
| 2018 | $255,426 | 658 | 432 |
| 2017 | $168,693 | 134 | 45 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.2M | 183 | 85.6% |
| Travel and Lodging | $72,190 | 161 | 5.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,950 | 18 | 4.8% |
| Food and Beverage | $47,574 | 1,873 | 3.5% |
| Unspecified | $10,991 | 3 | 0.8% |
Payments by Type
General
$1.4M
2,235 transactions
Research
$10,991
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER STUDY OF HTX-019 AS TREATMENT FOR POSTOPERATIVE NAUSEA AND VOMITING FOLLOWING FAILED ANTIEMETIC PROPHYLAXIS | Heron Therapeutics, Inc. | $10,991 | 0 |
Top Doctors Receiving Payments for CINVANTI — Page 42
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Diagnostic Radiology | Houston, TX | $11.83 | 1 |
| , M.D | Radiation Oncology | Kingwood, TX | $11.83 | 1 |
| , MD | Nephrology | Charleston, WV | $11.78 | 1 |
| , MD PHD | Hematology & Oncology | Decatur, IL | $11.73 | 1 |
| , MD | Radiation Oncology | Decatur, IL | $11.73 | 1 |
| , MD | Radiation Oncology | Effingham, IL | $11.73 | 1 |
| , M.D | Hematology & Oncology | Decatur, IL | $11.73 | 1 |
| , M.D | Hematology & Oncology | Jonesboro, AR | $11.69 | 1 |
| , MD | Medical Oncology | Jonesboro, AR | $11.69 | 1 |
| , M.D | Hematology & Oncology | Atlanta, GA | $11.63 | 1 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $11.61 | 1 |
| , M.D | Radiation Oncology | Beverly Hills, CA | $11.61 | 1 |
| , MD, PHD, MPH | Hematology & Oncology | Beverly Hills, CA | $11.61 | 1 |
| , M.D | Medical Oncology | Los Angeles, CA | $11.61 | 1 |
| , MD | Diagnostic Radiology | Santa Monica, CA | $11.61 | 1 |
| Liam Boyle | — | York, PA | $11.53 | 1 |
| , MD, PHD | Hematology | Titusville, FL | $11.48 | 1 |
| , M.D | Internal Medicine | Vineland, NJ | $11.42 | 1 |
| , D.O | Internal Medicine | Rogers, AR | $11.41 | 1 |
| , MD | Radiation Oncology | Lincoln, NE | $11.41 | 1 |
| , MD | Hematology & Oncology | Orange, CA | $11.37 | 1 |
| , M.D | Hematology & Oncology | Orange, CA | $11.37 | 1 |
| , M.D | Specialist | Orange, CA | $11.37 | 1 |
| , M.D | Hematology & Oncology | Sumter, SC | $11.32 | 1 |
| , M.D | Hematology | Inverness, FL | $11.29 | 1 |
Ad
Manufacturing Companies
- Heron Therapeutics, Inc. $1.4M
Product Information
- Type Drug
- Total Payments $1.4M
- Total Doctors 1,159
- Transactions 2,238
About CINVANTI
CINVANTI is a drug associated with $1.4M in payments to 1,159 healthcare providers, recorded across 2,238 transactions in the CMS Open Payments database. The primary manufacturer is Heron Therapeutics, Inc..
Payment data is available from 2017 to 2024. In 2024, $889.20 was paid across 13 transactions to 11 doctors.
The most common payment nature for CINVANTI is "Consulting Fee" ($1.2M, 85.6% of total).
CINVANTI is associated with 1 research study, including "A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER STUDY OF HTX-019 AS TREATMENT FOR POSTOPERATIVE NAUSEA AND VOMITING FOLLOWING FAILED ANTIEMETIC PROPHYLAXIS" ($10,991).